Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
Tazemetostat hydrobromide by Ipsen for Peripheral Nerve Sheath Tumor (Neurofibrosarcoma): Likelihood of Approval
Tazemetostat hydrobromide is under clinical development by Ipsen and currently in Phase II for Peripheral Nerve Sheath Tumor (Neurofibrosarcoma). According...
Tazemetostat hydrobromide by Ipsen for Chordoma: Likelihood of Approval
Tazemetostat hydrobromide is under clinical development by Ipsen and currently in Phase II for Chordoma. According to GlobalData, Phase II...
Tazemetostat hydrobromide by Ipsen for Chondrosarcoma: Likelihood of Approval
Tazemetostat hydrobromide is under clinical development by Ipsen and currently in Phase II for Chondrosarcoma. According to GlobalData, Phase II...
Tazemetostat hydrobromide by Ipsen for Non-Hodgkin Lymphoma: Likelihood of Approval
Tazemetostat hydrobromide is under clinical development by Ipsen and currently in Phase II for Non-Hodgkin Lymphoma. According to GlobalData, Phase...
Tazemetostat hydrobromide by Ipsen for Small-Cell Lung Cancer: Likelihood of Approval
Tazemetostat hydrobromide is under clinical development by Ipsen and currently in Phase I for Small-Cell Lung Cancer. According to GlobalData,...